ABSTRACT
BACKGROUND: Evidence suggests that small airways contribute to clinically significant processes in asthma. Cysteinyl leukotrienes (CysLTs) are considered to be pivotal mediators in the pathogenesis of asthma. Montelukast (MK), a specific CysLT1 receptor antagonist, is metabolized in two main hydroxylated metabolites (termed M5 and M6, respectively). OBJECTIVES: The aims of this study were to compare the responsiveness of small and large human bronchi to the three CysLTs, to evaluate the antagonist activity of MK, M5 and M6 in these preparations of human bronchi, and to characterize the CysLT receptors involved in the contractile response. METHODS AND RESULTS: In isolated small bronchus (i.d. 0.5-2 mm), the potencies (-log molar EC50) of LTC4, LTD4 and LTE4 were 9.3 (n=11), 9.1 (n=30) and 8.4 (n=14), respectively. The three CysLTs were about 30-fold more potent in small bronchi than in larger bronchi (i.d. 4-6 mm). In small bronchi, MK significantly shifted to the right the CysLT concentration-effect curves with pA2 values against LTC4, LTD4 and LTE4 of 9.1 (n=3), 9.0 (n=11) and 8.7 (n=5), respectively. The antagonist potencies of M6 and M5 were similar to MK and fivefold lower, respectively. A similar activity of MK against the three CysLTs suggested that CysLT1 receptors are involved in the contraction of human bronchus. Analysis by RT-PCR also indicated that human bronchus mainly expressed CysLT1 receptors. CONCLUSION: MK exerts a potent antagonist activity against the particularly potent constricting effects of CysLTs in isolated human small bronchi, which only expressed the CysLT1 receptor subtype. The metabolites of MK are also potent in vitro antagonists, but may not participate in the therapeutic activity of MK due to their low plasma concentrations in patients treated with the recommended dose of MK.
Subject(s)
Acetates/pharmacology , Bronchi/drug effects , Leukotriene Antagonists/pharmacology , Quinolines/pharmacology , Acetates/metabolism , Adult , Aged , Aged, 80 and over , Bronchial Hyperreactivity , Bronchial Provocation Tests , Cyclopropanes , Dose-Response Relationship, Drug , Female , Humans , In Vitro Techniques , Leukotriene Antagonists/metabolism , Leukotriene C4/antagonists & inhibitors , Leukotriene C4/pharmacology , Leukotriene D4/antagonists & inhibitors , Leukotriene D4/pharmacology , Leukotriene E4/antagonists & inhibitors , Leukotriene E4/pharmacology , Male , Middle Aged , Quinolines/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , SulfidesABSTRACT
Neurokinins (mainly substance P and neurokinin A) are released by sensitive nerve fibres. These fibres have been found in the vascular wall of arteries and veins of many vascular regions, particularly in nasal mucosa vessels, temporal and coronary arteries and saphenous veins. Substance P causes vascular relaxation by stimulating NK1 endothelial receptors. This relaxant effect is mediated, according to the vessels, by nitric oxide (NO), prostanoids or endothelium-dependent hyperpolarizing factor (EDHF). Capsaïcin, which induces the release of neurokinins, and neurokinin A can cause contractions of some vascular preparations, suggesting the existence of smooth muscle NK2 receptor associated with contraction. The vasodilatation induced by substance P injection appears reduced in patients with cardiovascular risk factors. The clinical development of specific neurokinin receptor antagonists may give the opportunity to specify the role of neurokinins in systemic vascular diseases. The results already obtained after repeated local applications of capsaïcin (to reduce local levels of neurokinins) in vasomotor rhinitis and urticaria suggest that the vascular effects of neurokinins may participate in the clinical expression of these diseases.
Subject(s)
Blood Vessels/physiology , Neuropeptides/physiology , Tachykinins/physiology , Blood Vessels/drug effects , Humans , Neuropeptides/pharmacology , Substance P/pharmacology , Substance P/physiology , Tachykinins/pharmacology , Vasodilation/physiologyABSTRACT
7-Hydroxycoumarin (CAS 93-35-6, 7-HC) is the main coumarin (1,2-benzopyrone) metabolite and the therapeutic active molecule. It exhibits antioxidant properties in vitro and may share with other coumarin derivatives vasodilator effects. The aim of the study was to assess the effects of 7-HC on isolated perfused and ischemic-reperfused rat heart. After a 10-min perfusion, an increase in the coronary flow was observed with 7-HC at 10(-4) mol/l (p = 0.002) as well as an increase in left ventricular developed pressure with 7-HC at 10(-5) mol/l (p = 0.038). The increase in coronary flow is not solely explained by the increase in inotropism. It appears to be also induced through a direct vasodilator effect which, however, does not involve the release of vasodilator prostaglandins since it was not inhibited by indometacin. After the 30-min global ischemia and the 45-min reperfusion period, 7-HC at 10(-5) mol/l induced an increase in left ventricular developed pressure (p = 0.042) and in the ratio of heart rate x left ventricular developed pressure over oxygen consumption (p = 0.036).
